Thymoquinone Ameliorates Doxorubicin-Induced Cardiotoxicity in Swiss Albino Mice by Modulating Oxidative Damage and Cellular Inflammation
Overview
Authors
Affiliations
Thymoquinone is the active constituent of , having antioxidant and anti-inflammatory actions. In present study, we have analyzed the effects of thymoquinone on doxorubicin (DOX) induced cardiotoxicity in mice. In this experiment, thirty mice (25-35 gm) were divided into five groups (Groups A, B, C, D, and E) each containing six animals. Normal saline was given to a control group (Group A) for 14 days. Cardiotoxicity was induced by DOX (15 mg/kg, i.p.) in Group B, once on the 13th day of the study, and Groups C and D also received DOX (15 mg/kg, i.p.) and were then treated with thymoquinone (10 and 20 mg/kg, b/w, p.o.), respectively, for 14 days. Group E was given only thymoquione (20 mg/kg b/w, p.o.). A blood serum marker (AST, ALT, CK-MB, and LDH) and oxidative stress marker (LPO, GSH, CAT, SOD, GPx, GR, and GST) were evaluated. Results revealed that serum enzyme marker like aspartate aminotransferase (AST), creatinine kinase-MB (CKMB), and lactate dehydrogenase (LDH) were significantly elevated in Group B as compare to Group A. Similarly, the oxidative stress marker lipid peroxidation (LPO) was also elevated in Group B while the antioxidant enzyme catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase, and glutathione -transferase (CAT, SOD, GPx, GR, and GST) were also decreased in Group B. The treatment with thymoquinone 10 and 20 mg/kg resulted in a significant decrease in the serum marker and increase in the antioxidant enzymes. In this study, we have found that thymoquinone prevented DOX-induced cardiotoxicity by accelerating heart antioxidant defense mechanisms and down regulating the LPO levels towards normalcy in Groups C and D. The effect of doxorubicin increases the inflammatory cytokine (IL2) in Group B as compared to Group A, and it overcomes by the thymoquinone in Groups C and D. Thus, thymoquinone may have utility as a potential drug for cardiomyopathy.
Verma A, Anwer T, Iqbal M, Gahlot V, Khan R, Sharma M Open Med (Wars). 2025; 20(1):20241130.
PMID: 40028266 PMC: 11868710. DOI: 10.1515/med-2024-1130.
Behdokht B, Foad N, Saeed N, Ahmadi N, Sakineh A J Pharmacopuncture. 2024; 27(3):245-252.
PMID: 39350925 PMC: 11439521. DOI: 10.3831/KPI.2024.27.3.245.
Farooq J, Sultana R, James J, Fathima C Z, Almutairy A, Hussain A Toxics. 2024; 12(9).
PMID: 39330616 PMC: 11435605. DOI: 10.3390/toxics12090688.
Aslani M, Saadat S, Boskabady M Iran J Basic Med Sci. 2024; 27(8):923-951.
PMID: 38911247 PMC: 11193497. DOI: 10.22038/IJBMS.2024.75985.16453.
Hafez M, Ez Elarab S, Tohamy H, El-Far A Sci Rep. 2024; 14(1):13016.
PMID: 38844763 PMC: 11156670. DOI: 10.1038/s41598-024-62780-y.